MIK665 is primarily utilized in the field of oncology, specifically targeting cancers that are driven by the overexpression or dysregulation of the MCL-1 protein. This small molecule inhibitor is designed to bind to MCL-1, a protein that plays a critical role in preventing apoptosis (programmed cell death) in cancer cells. By inhibiting MCL-1, MIK665 promotes the death of cancer cells, making it a promising therapeutic agent for treating various types of cancers, including hematologic malignancies like multiple myeloma, acute myeloid leukemia (AML), and certain solid tumors. Its application is particularly significant in cases where cancer cells have developed resistance to other forms of treatment, as MCL-1 is often involved in such resistance mechanisms. Research and clinical trials are ongoing to evaluate its efficacy, safety, and potential combination with other anticancer therapies.